Calcium channel blockers and β-blockers in relation to Parkinson's disease
| Autor: | Thanh G.N. Ton, Walter A. Kukull, Susan R. Heckbert, Gary M. Franklin, Mary Anne Rossing, Terri Smith-Weller, Phillip D. Swanson, W. T. Longstreth, Harvey Checkoway |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male Risk medicine.medical_specialty Time Factors Parkinson's disease Adrenergic beta-Antagonists Population Article Community Health Planning Internal medicine Epidemiology Confidence Intervals Odds Ratio medicine Humans education Aged Retrospective Studies Aged 80 and over education.field_of_study business.industry Calcium channel Case-control study Parkinson Disease Retrospective cohort study Odds ratio Middle Aged Calcium Channel Blockers medicine.disease Confidence interval Endocrinology Neurology Case-Control Studies Female Neurology (clinical) Geriatrics and Gerontology business |
| Zdroj: | Parkinsonism & Related Disorders. 13:165-169 |
| ISSN: | 1353-8020 |
| DOI: | 10.1016/j.parkreldis.2006.08.011 |
| Popis: | We investigated the risk of Parkinson's disease (PD) associated with calcium channel blockers (CCBs) and beta-blockers in a population-based case-control study of 206 men and women between ages 35 and 89 with a new diagnosis of idiopathic PD between 1992 and 2002, and 383 controls without PD or other neurodegenerative disorders who were frequency matched on age, sex, duration of GHC enrollment and clinic. The adjusted odds ratio associated with ever use was 0.85 (95% confidence interval [CI]: 0.43, 1.66) for CCBs, and 1.20 (95% CI: 0.71, 2.03) for beta-blockers. We observed no association with PD risk for either class of medication in terms of duration, dose, number of prescriptions or pattern of use. The weakness of these associations and the absence of additional influence of dose or duration of use argue against any causal interpretation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect